Multiple sclerosis research

Dec 04, 2017

Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

Nov 17, 2017

Multiple Sclerosis: KOL Insight 2016

Nov 09, 2017

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis

Oct 27, 2017

Merck KGaA Darmstadt, Germany Announces Recipients of EUR1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017

Oct 18, 2017

Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

Oct 10, 2017

National MS Society Commits Nearly $14 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever

Sep 05, 2017

Investigational Cladribine Tablets Demonstrates Sustained Disease Control over 4 Years with Maximum of 20 Days Oral Treatment